March 16th 2023
Kidney Cancer Association president Gretchen Vaughan discusses improvements being rolled out by the organization and the importance of multidisciplinary care.
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Cases and Conversations™: How The Experts Make Evidence-Based Treatment Decisions in Castration-Resistant Prostate Cancer
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Receiving a Diagnosis of RCC: Patient and Caregiver PerspectivesMarch 2nd 2023
Shared insight from Terri Blalock and her caregiver, Kaitlin Blalock, regarding the diagnosis of renal cell carcinoma Terri received following a number of symptoms.
PET/CT Imaging Agent Demonstrates Real-World Specificity/Sensitivity in RCCFebruary 20th 2023
89Zr-DFO-girentuximab improves sensitivity and specificity in identifying clear cell kidney cancer compared with any metric to date, according to an expert from the University of California, Los Angeles.
Frontline Cabozantinib Yields Early Responses After CPI Combos in RCCFebruary 19th 2023
Patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who receive first-line cabozatinib after checkpoint inhibitor combination therapy appear to have early responses.
Cabozantinib Combo Shows Boost in Efficacy in Advanced Kidney Cancer SubgroupsFebruary 18th 2023
When combined with nivolumab and ipilimumab, cabozantinib appears to improve outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among the poor-risk population.
Long-Term Stereotactic Ablative Body Radiotherapy Demonstrates Lasting Efficacy/Safety in Kidney Cancer SubtypeJanuary 12th 2023
Data from a meta-analysis suggest that single-fraction stereotactic ablative body radiotherapy could result in a lower incidence of local failure than multifractionated radiation in patients with renal cell carcinoma.
First-Line Therapy for Advanced RCC: Optimizing Adverse Event ManagementJanuary 2nd 2023
A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.
Overview of First-Line Treatment Options for Advanced RCCJanuary 2nd 2023
Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.
‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says ExpertDecember 28th 2022
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Why European Experts Cautiously Recommend Pembrolizumab to Treat High-Risk Kidney Cancer Following SurgeryDecember 27th 2022
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
‘Number of Unanswered Questions’ Remain About Role of Stereotactic Radiation in Metastatic Kidney CancerDecember 26th 2022
An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.
Urologists Should Make Patients With Metastatic Kidney Cancer Aware that not All Trials Have Positive Results, Says ExpertDecember 25th 2022
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
‘Interesting’ Research Continues to Assess the Role of Radiation in Management of Metastatic Kidney CancerDecember 21st 2022
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
Interpreting Adjuvant Therapy Trial Results in Advanced RCCDecember 19th 2022
Before closing out their discussion on the evolving treatment landscape of advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, highlight clinical trials in the adjuvant setting.
Advanced Renal Cell Carcinoma: Nuancing Triplet Therapy Trial ResultsDecember 19th 2022
Shared insight on the results from triplet therapy–centered clinical trials in advanced renal cell carcinoma and how these might inform treatment strategies as the paradigm continues to evolve.
First-Line Clinical Trial Data in Advanced Renal Cell CarcinomaDecember 12th 2022
A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice.
Renal Cell Carcinoma: Overlapping Toxicity in TKI/IO Combination TherapyDecember 5th 2022
Closing out their discussion on adverse event management in advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, consider overlapping toxicity in TKI/IO regimens.